Pasar al contenido principal

FRUCTOSA-1,6-BISFOSFATO ALDOLASA B, UN NODO CENTRAL EN LA ESTEATOSIS HEPATICA Y LA RESISTENCIA A LA INSULINA

PID2022-139395OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOC INSTITUTO DE INVESTIGACION SANITARIA BIOBIZKAIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis

  • Mercado-Gómez, Maria
  • Goikoetxea-Usandizaga, Naroa
  • Kerbert, Annarein J.C.
  • Uraga Gracianteparaluceta, Leire
  • Serrano-Maciá, Marina
  • Lachiondo-Ortega, Sofía
  • Rodríguez-Agudo, Rubén
  • Gil-Pitarch, Clàudia
  • Simón, Jorge
  • González-Recio, Irene
  • Fondevila, Marcos F.
  • Santamarina-Ojeda, Pablo
  • Fraga, Mario F.
  • Nogueiras, Rubén
  • Heras, Javier de las
  • Jalan, Rajiv
  • Martínez-Chantar, María Luz
  • Delgado, Teresa C.
[Introduction]: Ammonia is a pathogenic factor implicated in the progression of metabolic-associated steatotic liver disease (MASLD). The contribution of the glutaminase 1 (GLS) isoform, an enzyme converting glutamine to glutamate and ammonia, to hepatic ammonia build-up and the mechanisms underlying its upregulation in metabolic-associated steatohepatitis (MASH) remain elusive., [Methods]: Multiplex transcriptomics and targeted metabolomics analysis of liver biopsies in dietary mouse models representing the whole spectra of MASLD were carried out to characterize the relevance of hepatic GLS during disease pathological progression. In addition, the acute effect of liver-specific GLS inhibition in hepatic ammonia content was evaluated in cultured hepatocytes and in in vivo mouse models of diet-induced MASLD. Finally, the regulatory mechanisms of hepatic GLS overexpression related to the lipopolysaccharide (LPS)/Toll-like receptor 4 (TLR4) axis were explored in the context of MASH., [Results]: In mouse models of diet-induced MASLD, we found that augmented liver GLS expression is closely associated with the build-up of hepatic ammonia as the disease progresses from steatosis to steatohepatitis. Importantly, the acute silencing/pharmacological inhibition of GLS diminishes the ammonia burden in cultured primary mouse hepatocytes undergoing dedifferentiation, in steatotic hepatocytes, and in a mouse model of diet-induced steatohepatitis, irrespective of changes in ureagenesis and gut permeability. Under these conditions, GLS upregulation in the liver correlates positively with the hepatic expression of TLR4 that recognizes LPS. In agreement, the pharmacological inhibition of TLR4 reduces GLS and hepatic ammonia content in LPS-stimulated mouse hepatocytes and hyperammonemia animal models of endotoxemia., [Conclusions]: Overall, our results suggest that the LPS/TLR4 axis regulates hepatic GLS expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis., TC Delgado is funded by “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por El FSE invierte en tu future”. This work was supported by the Gilead Sciences Research Scholars Program in Global Liver (to TCD), Nanostring® grant (to TCD); grant from Ministerio de Ciencia, Innovación y Universidades (MICINN: PID2022-139395OB-100 integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, con Fondos FEDER); grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116RB-I00 CEX2021-001136-S integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER for (MLM-C); Project funded by CIBEREHD; La Caixa Scientific Foundation (HR17-00601) (for MLM-C); ERA-Net E-Rare EJP RD Joint Translational Call for Rare Diseases FIGHT-CNNM2 (EJPRD19-040), and from Instituto Carlos III, Spain (for MLM-C, JH); the Basque Department of Education (IT1739-22) (for JH). JH and TCD are members of the European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN) Project ID No. 739543., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed